Opinion|Videos|January 20, 2025
Treatment Choices For PPD and Peripartum Depression
Panelists discuss the strategic decision-making process for choosing among selective serotonin reuptake inhibitors (SSRIs), rapid-onset treatments like zuranolone, and nonmedication therapies for postpartum depression (PPD), emphasizing the importance of treatment speed, severity of symptoms, and patient preferences.
Advertisement
Episodes in this series
Advertisement
Related to this article
How VA clinicians treat veterans’ PTSD while managing suicide risk, using shared decisions, safety planning, and phase-based trauma therapies.
RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Discover how integrated psychotherapy—CBTp, family support, and relapse plans—boosts schizophrenia recovery alongside antipsychotics.
FDA grants Breakthrough Device status to NET Recovery’s tACS wearable, aiming to curb cocaine and meth use and close a major treatment gap.
Learn how IPV shapes mental health from pregnancy to adulthood, and how clinicians assess risk, plan safety, and treat victims and perpetrators.
Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
2
Using Psychotherapy for the Prevention of Relapse in Schizophrenia
3
Positive Phase 2 Topline Results: Remlifanserin for the Treatment of Alzheimer Disease Psychosis
4
Searching for a New TMS Target in Schizophrenia, With Andrew Pines, MD
5